# A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer

> **NCT07701486** · PHASE1,PHASE2 · RECRUITING · sponsor: **Theriva Biologics SL** · enrollment: 6 (estimated)

## Conditions studied

- Pancreas Cancer, Metastatic
- Pancreas Cancer, Stage IV
- Ductal Adenocarcinoma of the Pancreas

## Interventions

- **BIOLOGICAL:** VCN-01 oncolytic adenovirus (zabilugene almadenorepvec)
- **DRUG:** Nab-paclitaxel + Gemcitabine

## Key facts

- **NCT ID:** NCT07701486
- **Lead sponsor:** Theriva Biologics SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-03
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07701486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07701486, "A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07701486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*